The U.S. Patent and Trademark Office granted Implanet two additional patents for the company's Jazz platform.
Here are four insights:
1. The two new patents add to the company's existing 22 patents, which cover all aspects of the Jazz platform.
2. The Jazz platform is designed to treat spinal pathologies requiring vertebral fusion surgery.
3. Implanet hopes to further strengthen its Jazz platform with future patents, noting the spine market is estimated at $2.1 billion.
4. CEO of Implanet Ludovic Lastennet said, "Obtaining these patents is an integral part of our value creation strategy. The systematic growth of our [intellectual property] protection enables us to reinforce our current commercial partnership and outlook towards future strategic alliances."